Transamerica named top choice for life insurance
Aegon's US business unit, Transamerica, has been named top choice for life insurance policies in four categories by leading US newspaper, USA Today.
The four categories were:
- Best no-exam life insurance – Transamerica earned four and a half stars for its Trendsetter® Super policy. USA Today highlighted the product’s extremely competitive pricing and high coverage amounts. The newspaper also mentioned the flexibility of multiple term lengths ranging from 10 to 30 years and the fact that coverage can be renewed up to the age of 105 — the highest in the newspaper’s analysis.
- Best for living benefits – Awarding Transamerica four stars, USA Today noted that the Trendsetter® LB term life insurance policy includes living benefits for terminal, chronic, or critical illnesses at no additional premium cost.
- Best for buyers in their 50s – USA Today gave Transamerica’s Trendsetter® Super term life insurance policy a four star rating due to the product having some of the lowest premiums for individuals in their 50s. The newspaper also noted that Transamerica’s maximum issue age is 80 — one of the highest amongst the insurance companies reviewed.
- Best for seniors – Giving it a four star rating, USA Today noted that Transamerica’s Trendsetter® LB term life policy included living benefits.
To determine the best life insurance companies, USA Today evaluated 28 of the top life insurance companies that offer coverage in the United States. Each life insurance company had the opportunity to earn up to 100 points based on several factors including rates, reliability of policy illustrations and financial strength.
These accolades come at an important time for Transamerica. At Aegon’s 2023 Capital Markets Day, the company outlined the steps it is taking to ensure that Transamerica captures its full potential. Transamerica has had a long and proud history, and Aegon aims to accelerate Transamerica’s growth in order to build America’s leading middle market life insurance and retirement company.